ArticleThe European respiratory journal2026

The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I

Catherine Drai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.